Capital Markets company Nuvama Wealth Management announced Q3FY26 results Revenue from operations: Q3FY26 came in at Rs 1,104 crore versus Rs 1,034 crore in Q3FY25, a rise of ~7%. Total income: Rs 1,106 crore for the quarter (change 7% YoY) and Rs 4,169 crore for FY25. Profit before tax: Rs 340 crore in Q3FY26, marginally higher than Rs 334 crore in the year-ago quarter. Net profit: Rs 254 crore for the quarter (change 1% YoY); FY25 net profit stood at Rs 985 crore. Basic EPS: Rs 14.02 for Q3FY26 (post 1:5 stock split) versus Rs 14.08 last year; FY25 basic EPS was Rs 55.33 before split, restated at ~Rs 11.07 on a split-adjusted basis (diluted EPS: Rs 53.71 pre-split). Wealth management: Generated Rs 697 crore revenue in Q3FY26 and Rs 2,293 crore in FY25; segment PBT for the quarter was Rs 140 crore. Asset management: Rs 36 crore revenue this quarter and Rs 125 crore in FY25; segment loss of Rs 4 crore in Q3FY26. Capital markets: Rs 408 crore revenue in Q3FY26; Rs 2,062 crore in FY25; segment PBT of Rs 205 crore in Q3FY26. Unallocated & inter-segment eliminations bring consolidated PBT to Rs 340 crore for the quarter. Result PDF
Conference Call with Radico Khaitan Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Syngene International Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Atul announced Q3FY26 results Revenue: Rs 1,573.62 crore against Rs 1,416.83 crore during Q3FY25, change 11%. PBT: Rs 203.48 crore against Rs 157.84 crore during Q3FY25, change 29%. PAT: Rs 163.54 crore against Rs 117.1 crore during Q3FY25, change 40%. EPS: 54.6 for Q3FY26. Result PDF
Non-Electrical Utilities company Gujarat State Petronet announced Q3FY26 results Consolidated Gross Income for Q3FY26 was Rs 4,187 crore, easing 3 % QoQ and 10 % YoY. Consolidated Profit before tax (PBT) rose to Rs 511 crore, up 6 % YoY but slightly below the Q2FY26 figure of Rs 527 crore. Consolidated PAT improved to Rs 379 crore in Q3, registering 13 % growth over the Rs 335 crore earned in Q3FY25; sequentially, it softened by Rs 10 crore. Q3FY26 throughput came in at 27.49 MMSCMD, marginally lower than 28.49 MMSCMD in Q2FY26 and down from 29.02 MMSCMD in the same quarter last year. Result PDF
Pharmaceuticals company Syngene International announced Q3FY26 results Revenue: Rs 944 crore against Rs 917 crore during Q3FY25, change 3%. EBITDA: Rs 302 crore against Rs 225 crore during Q3FY25, change 34%. PAT: Rs 131 crore against Rs 73 crore during Q3FY25, change 79%. PAT Margin: 14% for Q3FY26. Peter Bains, Managing Director & CEO, Syngene International, said: “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the underlying business has shown steady progress, with Research Services securing new programs and delivering continued growth. The highlight of the quarter was the extension of our collaboration with Bristol Myers Squibb through to 2035. This extension provides both partners with a strategic ten-year horizon to further develop and expand this unique, long-standing collaboration.” Deepak Jain, Chief Financial Officer, Syngene International, said: “Despite the ongoing impact of a single customer, revenue has been flat QoQ, reflecting the underlying positive trend of the business. Our strong balance sheet provides financial flexibility for continued investments in enhancing our capabilities and capacities to better serve our clients.” Result PDF